{"id":"NCT03131154","sponsor":"Aldeyra Therapeutics, Inc.","briefTitle":"SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.","officialTitle":"A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-26","primaryCompletion":"2019-04-19","completion":"2019-04-26","firstPosted":"2017-04-27","resultsPosted":"2025-02-10","lastUpdate":"2025-02-10"},"enrollment":123,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-infectious Anterior Uveitis"],"interventions":[{"type":"DRUG","name":"ADX-102 Ophthalmic Solution (0.5%)","otherNames":["Reproxalap"]},{"type":"DRUG","name":"Vehicle of ADX-102 Ophthalmic Solution","otherNames":["Vehicle of Reproxlap"]}],"arms":[{"label":"ADX-102 Ophthalmic Solution (0.5%)","type":"EXPERIMENTAL"},{"label":"Vehicle of ADX-102 Ophthalmic Solution","type":"PLACEBO_COMPARATOR"}],"summary":"A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.","primaryOutcome":{"measure":"Number of Subjects Who Meet Time to Clearance of Anterior Chamber Cells","timeFrame":"The efficacy assessment period was 4 weeks; baseline was defined as Day 1.","effectByArm":[{"arm":"ADX-102 Ophthalmic Solution (0.5%)","deltaMin":25,"sd":null},{"arm":"Vehicle Ophthalmic Solution","deltaMin":24,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":61},"commonTop":["Uveitis","Eye pain","General Disorders and Administration Site Conditions","Visual acuity reduced","Iridocyclitis"]}}